CTMX — CytomX Therapeutics, Inc. stock price, charts and financials

Latest market price

3.32

+0.15+4.73%

Overview Short InterestFilings

CTMXQT39CytomX Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

3.32+4.73%

Earnings

Up 4.7% — Earnings due 2026-08-06 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	6.64	EPS (ttm)	0.50	Insider Own	5.45%	Shs Outstand	160.82M	Perf Week	3.11%

Market Cap	533.93M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-2.20%	Shs Float	139.91M	Perf Month	-12.86%

Enterprise Value	376.93M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	28.82%	Perf Quarter	-20.57%

Income	42.00M	P/S	3.63	EPS this Y	-183.13%	Inst Trans	-	Short Ratio	9.51	Perf Half Y	-45.48%

Sales	147.00M	P/B	4.45	EPS next Y	-19.39%	ROA	-16.46%	Short Interest	40.32M	Perf YTD	-22.07%

Book/sh	0.75	P/C	3.38	EPS next 5Y	-	ROE	-36.61%	52W High	8.21 -59.56%	Perf Year	41.28%

Cash/sh	0.98	P/FCF	-	EPS past 3/5Y	-	ROIC	-19.70%	52W Low	1.72 93.02%	Perf 3Y	89.71%

Dividend Est.	-	EV/EBITDA	8.77	Sales past 3/5Y	12.77% 2.25%	Gross Margin	99.29%	Volatility	4.95% 5.15%	Perf 5Y	-38.97%

Dividend TTM	-	EV/Sales	2.56	EPS Y/Y TTM	31.58%	Oper. Margin	-181.92%	ATR (14)	0.18	Perf 10Y	-67.89%

Dividend Ex-Date	-	Quick Ratio	10.38	Sales Y/Y TTM	6.52%	Profit Margin	-166.40%	RSI (14)	46.61	Recom	2.19

Dividend Gr. 3/5Y	-	Current Ratio	10.38	EPS Q/Q	-137.04%	SMA20	-4.09%	Beta	2.13	Target Price	11.25

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	-80.39%	SMA50	-1.92%	Rel Volume	0.59	Prev Close	3.17

Employees	69	LT Debt/Eq	-0.19	Earnings	Aug 06	SMA200	-20.65%	Avg Volume	4.13M	Price	3.32

IPO Date	Oct 08, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.42% 119.08%	Net Debt/EBITDA	0.45	Volume	2,436,273	Change	4.73%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-19-26	Initiated	Wolfe Research	Outperform	$6.00
May-11-26	Reiterated	HC Wainwright & Co.	Buy	$11
Mar-18-26	Reiterated	Jefferies	Buy	$8.00
Mar-16-26	Reiterated	Oppenheimer	Perform	$7.00 → $12
Mar-16-26	Upgrade	JP Morgan	Neutral → Overweight
Feb-04-26	Reiterated	Barclays	Overweight	$8.00 → $10
Jan-20-26	Initiated	Guggenheim	Buy	$10
Jan-20-26	Reiterated	Barclays	Overweight	$6.00 → $8.00
Jan-20-26	Reiterated	Piper Sandler	Overweight	$3.25 → $10
Oct-21-25	Reiterated	Barclays	Overweight	$3.50 → $6.00

Latest News

Aug-03-26

Aug-03-2608:00AM

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officerglobenewswire.com

Jul-30-26

Jul-30-2608:00AM

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com

Jul-29-26

Jul-29-2603:45AM

ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMXdefenseworld.net

Jul-27-26

Jul-27-2608:00AM

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directorsglobenewswire.com

Jul-08-26

Jul-08-2601:01PM

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Whyzacks.com

Company

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	147	76	138	101	53	37	68	57	60
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	147	76	138	101	53	37	68	57	60
Selling, General and Administrative Excl. Other	31	30	30	30	43	39	36	37	34
Research and Development	80	69	83	78	112	114	113	132	104
Other Operating Expense	0	0	0	0	-1	0	0	-1	-1
Operating Income	37	-22	25	-6	-101	-116	-81	-111	-78
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	6	5	7	10	2	0	30	8	8
Net Income Before Taxes	43	-17	32	3	-99	-116	-51	-103	-70
Income Taxes	0	0	0	4	0	0	14	0	14
Consolidated Net Income	42	-17	32	-1	-99	-116	-65	-102	-85
Net Income From Continuing Operations	42	-17	32	-1	-99	-116	-65	-102	-85
Net Income	42	-17	32	-1	-99	-116	-65	-102	-85
EPS (Recurring)	0.50	-0.15	0.38	-0.01	-1.48	-1.26	-0.71	-2.26	-2.03
EPS (Basic, Before Extraordinaries)	0.50	-0.15	0.38	-0.01	-1.48	-1.26	-0.71	-2.26	-2.03
EPS (Diluted)	0.50	-0.15	0.38	-0.01	-1.48	-1.26	-0.71	-2.26	-2.03
EBITDA	43	-16	34	5	-97	-113	-78	-100	-76
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	6.64	—	2.71	—	—	—	—	—	—
Price To Sales Ratio	1.96	7.74	0.63	1.14	1.99	7.49	4.43	6.56	10.57
Gross Margin	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Operating Margin	25.17	-28.95	18.12	-5.94	-190.57	-313.51	-119.12	-194.74	-130.00
Net Margin	28.57	-22.37	23.19	-0.99	-186.79	-313.51	-95.59	-178.95	-141.67
Shares Outstanding	87	138	84	74	66	64	46	45	42
Market Capitalization	289	588	87	115	106	277	301	374	634
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ogden Christopher	Chief Financial Officer	Jun 15 '26	Sale	3.05	1,624	4,953	295,324	Jun 17
Chu Yu-Waye	Chief Medical Officer	Mar 17 '26	Sale	6.42	21,279	136,675	189,446	Mar 19
McCarthy Sean A.	CEO	Mar 17 '26	Sale	6.42	118,969	764,138	1,078,922	Mar 19
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 17 '26	Sale	6.42	31,492	202,273	300,760	Mar 19
Ogden Christopher	Chief Financial Officer	Mar 17 '26	Sale	6.42	19,323	124,112	296,948	Mar 19
McCarthy Sean A.	CEO	Nov 06 '25	Sale	4.54	101,793	461,906	987,891	Nov 10
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 16 '25	Sale	2.69	13,884	37,334	272,252	Jun 17
Ogden Christopher	Chief Financial Officer	Jun 16 '25	Sale	2.69	10,614	28,540	226,271	Jun 17
McCarthy Sean A.	CEO	Jun 16 '25	Sale	2.69	55,511	149,264	1,089,684	Jun 17
McCarthy Sean A.	CEO	Jun 13 '25	Option Exercise	0.00	150,000	0	1,145,195	Jun 17
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	286,136	Jun 17
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Sale	2.95	1,641	4,841	199,385	Jun 17
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	236,885	Jun 17
McCarthy Sean A.	CEO	Mar 18 '25	Sale	0.60	37,656	22,556	995,195	Mar 20
Ogden Christopher	Chief Financial Officer	Mar 18 '25	Sale	0.60	8,551	5,122	201,026	Mar 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.